GLP1-RAs mitigate the impact of T2DM on the progression of DKD by suppressing many of the inflammatory signaling pathways like the renal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [15,68]. This evidence concerns the gene GCG and diabetic kidney disease.